Oxytrol

Nocturia, Urinary Bladder, Overactive, Neurological Disorders + 8 more

Treatment

20 Active Studies for Oxytrol

What is Oxytrol

Oxybutynin

The Generic name of this drug

Treatment Summary

Oxybutynin, also known as Ditropan XL, is a medication used to treat the symptoms of overactive bladder (OAB). It was approved by the FDA in 1975 and is often prescribed as the first line of treatment for OAB. It helps reduce urinary symptoms such as urgency, frequency, and nocturia, which can cause social embarrassment and decrease quality of life. Oxybutynin has been optimized for safety and effectiveness in treating OAB.

Ditropan

is the brand name

image of different drug pills on a surface

Oxytrol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ditropan

Oxybutynin

1975

256

Effectiveness

How Oxytrol Affects Patients

Oxybutynin helps treat symptoms of overactive bladder, like having to go to the bathroom urgently and often. It does this by blocking a certain type of brain receptors, called muscarinic receptors. People taking oxybutynin may experience swelling of the face, tongue, and throat (angioedema). Other possible side effects include hallucinations, confusion, agitation, drowsiness, and difficulty operating machinery. If any of these side effects occur, the dosage of this drug may need to be adjusted.

How Oxytrol works in the body

Oxybutynin works to relax the bladder by blocking the activity of acetylcholine, a chemical messenger responsible for muscle movement. This reduces muscle spasms and increases the bladder's capacity, allowing you to control when you need to go to the bathroom. The active metabolite of oxybutynin targets muscarinic receptors, which are responsible for controlling muscle movements in the bladder.

When to interrupt dosage

The proposed measure of Oxytrol is contingent upon the identified condition, such as Neurological Disorders, Foley Catheterization and Nocturia. The amount of dosage is subject to the technique of delivery (e.g. Tablet, extended release or Patch) specified in the table beneath.

Condition

Dosage

Administration

Spinal Dysraphism

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Urinary Bladder, Overactive

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Neurological Disorders

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

increased frequency of urination

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Foley Catheterization

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Longterm Indwelling Ureteral Stent

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Nocturia

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Bladder Spasms

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Urinary Urgency

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Urinary Incontinence, Urge

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Overactive Bladder Syndrome

, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL

, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Transdermal, Patch - Transdermal, Patch, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Tablet, Solution - Oral, Solution, Topical, Gel - Topical, Spray, metered - Topical, Spray, metered

Warnings

Oxytrol Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Oxybutynin may interact with Pulse Frequency

Urinary Retention

Do Not Combine

uncontrolled narrow-angle glaucoma

Do Not Combine

Gastric Retention

Do Not Combine

There are 20 known major drug interactions with Oxytrol.

Common Oxytrol Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Oxybutynin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Oxybutynin.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Oxybutynin is combined with Aclidinium.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Oxybutynin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Oxybutynin.

Oxytrol Toxicity & Overdose Risk

The most toxic dose of oxybutynin in rats is 460mg/kg. Overdosing on oxybutynin may cause symptoms such as confusion, fever, irregular heartbeat, difficulty urinating, difficulty breathing, and paralysis, as well as unconsciousness. If an overdose is suspected, supportive care should be provided and activated charcoal should be administered with a cathartic agent. Two reported cases of overdose involved people taking a 100mg dose of oxybutynin along with alcohol, but the patients recovered after receiving treatment.

image of a doctor in a lab doing drug, clinical research

Oxytrol Novel Uses: Which Conditions Have a Clinical Trial Featuring Oxytrol?

79 investigations are currently being conducted to assess the potential of Oxytrol for treating Overactive Bladder Syndrome, Foley Catheterization and Neurological Ailments.

Condition

Clinical Trials

Trial Phases

Nocturia

4 Actively Recruiting

Not Applicable, Phase 4

Bladder Spasms

1 Actively Recruiting

Phase 2

Spinal Dysraphism

0 Actively Recruiting

Urinary Incontinence, Urge

5 Actively Recruiting

Not Applicable, Phase 4

Foley Catheterization

0 Actively Recruiting

Urinary Urgency

2 Actively Recruiting

Not Applicable

Urinary Bladder, Overactive

0 Actively Recruiting

Overactive Bladder Syndrome

26 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 2, Phase 3

Longterm Indwelling Ureteral Stent

0 Actively Recruiting

Neurological Disorders

7 Actively Recruiting

Not Applicable, Phase 2

increased frequency of urination

3 Actively Recruiting

Not Applicable

Oxytrol Reviews: What are patients saying about Oxytrol?

5

Patient Review

7/31/2014

Oxytrol for Problems with Bladder Control

We tried this on our granddaughter who was having accidents day and night, and it worked like a charm! We've been using it for over 6 months now with great results.

5

Patient Review

2/1/2021

Oxytrol for Frequent Urination

I'm a 63-year-old man who had his prostate removed 10 years ago. Recently, I started feeling the urge to urinate constantly (even though there was no leakage) and the sensation that leakage was occurring. After trying different drugs prescribed by urologists with no success, I looked online for answers and found this product. I've been using it for three months now and am totally satisfied. I believe the low dosage is what works for men. Urologists need to be more open to this treatment option for their male patients.

5

Patient Review

7/13/2015

Oxytrol for Overactive Bladder

So far, so good! This has helped me a lot in just one week with no adverse effects.

5

Patient Review

11/6/2014

Oxytrol for Overactive Bladder

I'm really pleased with this patch! It helped me a lot and I didn't have any problems with the adhesive.

4.7

Patient Review

2/18/2015

Oxytrol for Problems with Bladder Control

I quickly noticed an improvement in my symptoms after using this treatment. I no longer needed to urinate as frequently and could sleep through the night without interruption. The only downside is that the patch can sometimes come loose, but overall this has been a huge help.

4.3

Patient Review

6/6/2015

Oxytrol for Overactive Bladder

I found significant relief from using this patch. I was able to extend the time between applications by moving it around on my lower body. It also helped to reduce itching. When removing the patch, be sure to soap up the area.

4

Patient Review

1/27/2018

Oxytrol for Overactive Bladder

I've been using these patches for a few years now and they're great! I haven't experienced any negative side effects. They definitely help me go less often, except when I'm anxious or something. The only downside is that they're pricey.

2.7

Patient Review

7/15/2021

Oxytrol for Problems with Bladder Control

I got a rash from using this patch, as well as blisters around the edge. I also didn't notice any change to my bladder after using it 3 times, so I stopped.

2.3

Patient Review

8/21/2014

Oxytrol for Overactive Bladder

While this product does help with leakage, I still find myself having to go frequently. Additionally, it's very clingy and hard to remove from the packaging; tape usually falls off after bathing. Finally, it leaves black marks which are difficult to scrub off.

2

Patient Review

1/10/2016

Oxytrol for Frequent Urination

I developed a large, red oozing rash that has not gone away after 24 hours. It's still a runny gooey mess. I thought it would dry up after removing the patch (used 2 days) but no such luck. I will call the hotline on Monday when it opens but I am very concerned. Do not use!

1.7

Patient Review

1/4/2016

Oxytrol for Frequent Urination

I started using this patch and, after only three days, began to notice blood in my urine. By the fifth day (I was on my second patch), I was having a full-blown period--even though I had just stopped bleeding two days before starting the patch. I also started experiencing dry skin on my face. So, I removed the patch on the sixth day and have continued to bleed heavily since then (it is now the seventh day).

Patient Q&A Section about oxytrol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is Oxytrol discontinued?

"According to Wilkes (2015), Bayer AG stopped distributing the OTC version of OXY-TDS in early 2015 because sales results were disappointing."

Answered by AI

Can you buy Oxytrol over-the-counter?

"The Oxytrol® skin patch is only available with a doctor's prescription for men, while women can get it without a prescription or over-the-counter (OTC). This product comes in two forms: Patch, Extended Release."

Answered by AI

What is Oxytrol used for?

"Oxybutynin is used to treat an overactive bladder. By relaxing the muscles in the bladder, oxybutynin improves symptoms such as the inability to control urination (incontinence), feeling that one has to urinate (urgency), and having to go to the bathroom often (frequency)."

Answered by AI

How long does it take for Oxytrol to work?

"It takes approximately one week for the medicine in Oxytrol (oxybutynin) patches to build up to steady levels in your system. The patch continuously releases the medication through your skin and into your bloodstream over the course of 3-4 days."

Answered by AI

Clinical Trials for Oxytrol

Image of Stanford Medicine Department of Obstetrics & Gynecology in Palo Alto, United States.

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder

22 - 80
Female
Palo Alto, CA

The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.

Waitlist Available
Device

Stanford Medicine Department of Obstetrics & Gynecology (+10 Sites)

Mickey Karram, MD

InMode MD Ltd.

Have you considered Oxytrol clinical trials?

We made a collection of clinical trials featuring Oxytrol, we think they might fit your search criteria.
Go to Trials

Have you considered Oxytrol clinical trials?

We made a collection of clinical trials featuring Oxytrol, we think they might fit your search criteria.
Go to Trials
Image of Rossignol Medical Center in Phoenix, United States.

Photobiomodulation for Autism

4 - 12
All Sexes
Phoenix, AZ

For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical practice of treating autism. At the beginning, at five weeks, and at the end of study, the clinician will complete the CARS-2, SRS, CGI, and a caregiver interview; additionally, questionnaires will be administered to caregivers during one of the 1-hour weekly treatment sessions.

Phase 2
Recruiting

Rossignol Medical Center

Richard E Frye, M.D., Ph.D

Image of Mickey Karram MD in Corona Del Mar, United States.

Nerve Ablation for Overactive Bladder

21 - 80
Female
Corona Del Mar, CA

The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder The main questions it aims to answer are: •Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. \[Time Frame: 3 months\] Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis. Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment.

Waitlist Available
Has No Placebo

Mickey Karram MD (+2 Sites)

Mickey Karram, MD

InMode MD Ltd.

Have you considered Oxytrol clinical trials?

We made a collection of clinical trials featuring Oxytrol, we think they might fit your search criteria.
Go to Trials